The JAK2 V617F mouse tumor model is an essential preclinical platform for studying myeloproliferative neoplasms and evaluating JAK-targeted therapies. This article provides a comprehensive technical guide covering model establishment strategies, sample types, validated testing items, and analytical methods. Researchers in hematology-oncology will find practical insights into disease monitoring, endpoint validation, and translational applications.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function point substitution (c.1849G>T) located in the pseudokinase (JH2) domain of the Janus kinase 2 gene. This mutation abrogates the autoinhibitory function of the JH2 domain, resulting in constitutive activation of the JAK-STAT signaling pathway and uncontrolled myeloproliferation. The mutation is detected in approximately 95% of polycythemia vera patients, 60% of essential thrombocythemia patients, and 50% of primary myelofibrosis patients, making it a hallmark driver lesion of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs).
Establishing a JAK2 V617F mouse tumor model enables researchers to reproduce the human disease phenotype in vivo, including erythrocytosis, marked splenomegaly, extramedullary hematopoiesis, progressive myelofibrosis, and, in some configurations, leukemic transformation. Two principal strategies dominate current experimental practice: retroviral bone marrow transplantation models and genetically engineered transgenic or knock-in models. Each approach offers distinct advantages with respect to disease latency, reproducibility, and experimental throughput, and the selection depends on the specific research objective, whether it is therapeutic screening, pathogenesis studies, or biomarker validation.
Testing Samples
Transduced Hematopoietic Cell Lines
Ba/F3 cells engineered to express the erythropoietin receptor and JAK2 V617F, along with HEL cells carrying the endogenous mutation, are frequently used as in vitro pilot systems. These samples are collected following retroviral transduction and antibiotic selection to verify transgene expression, cytokine-independent proliferation, and constitutive STAT phosphorylation before in vivo transplantation.
Primary Donor Bone Marrow Cells
Bone marrow is harvested from the femurs and tibias of donor mice, typically BALB/c or C57BL/6 strains, 4 to 5 days after 5-fluorouracil preconditioning (150 mg/kg, intraperitoneal) to enrich for cycling hematopoietic progenitors. These cells serve as the substrate for retroviral transduction in transplantation-based model establishment.
Peripheral Blood
Serial blood samples collected from the tail vein or submandibular vein at defined time points are used for complete blood counts, mutant allele burden quantification, and flow cytometric monitoring of disease progression throughout the study.
Spleen and Liver Tissues
At terminal collection, spleen and liver specimens are weighed, photographed, and processed for histopathology, immunophenotyping, and molecular analysis. Splenomegaly and hepatomegaly are cardinal macroscopic indicators of disease burden and extramedullary hematopoiesis.
Genomic DNA and Protein Extracts
High-quality genomic DNA extracted from blood, bone marrow, and solid organs is required for genotyping and quantitative allele burden assays. Total protein lysates from hematopoietic cells are prepared for Western blot assessment of downstream signaling molecules such as phosphorylated STAT5, STAT3, and ERK.
Testing Items
A comprehensive testing panel for the JAK2 V617F model establishment experiment typically includes the following validated endpoints:
- Genotyping confirmation of the JAK2 V617F transgene or knock-in allele in donor cells and recipients
- Quantification of mutant allele burden by quantitative PCR or droplet digital PCR
- Complete blood count analysis, including white blood cell count, red blood cell count, hematocrit, hemoglobin, and platelet count
- Gross pathology assessment of spleen weight, liver weight, and body weight ratios
- Histopathological evaluation of bone marrow, spleen, and liver using hematoxylin and eosin staining
- Reticulin and trichrome staining for grading of myelofibrosis
- Flow cytometric immunophenotyping of myeloid, erythroid, and megakaryocytic lineages
- Western blot or intracellular flow cytometry for phosphorylated STAT5 as a pharmacodynamic marker
- Colony-forming unit assays assessing erythroid colony growth and cytokine independence
- Survival analysis and clinical scoring for terminal disease endpoints
Testing Methods
Retroviral Transduction and Bone Marrow Transplantation
In the transplantation model, donor mice receive 5-fluorouracil to mobilize progenitor cells, which are then harvested and cultured in cytokine-rich medium containing stem cell factor, IL-3, and IL-6. Cells undergo two rounds of spinoculation with replication-defective retrovirus encoding JAK2 V617F, usually coupled with a GFP reporter. Transduced cells are injected intravenously into lethally irradiated (9.5 Gy) syngeneic recipient mice. Disease typically manifests within 3 to 4 weeks, with GFP chimerism in peripheral blood serving as an early engraftment indicator.
Genetically Engineered Mouse Models
Conditional knock-in mice carrying the JAK2 V617F mutation in the endogenous Jak2 locus are crossed with hematopoietic-specific Cre driver lines such as Vav-Cre or inducible Mx1-Cre. This approach preserves physiological expression levels and produces a disease course that closely mimics human MPN progression from polycythemia to myelofibrosis over several months.
Molecular Quantification
Mutant allele burden is quantified using allele-specific TaqMan qPCR assays or droplet digital PCR, which offers superior sensitivity for detecting low-level chimerism and monitoring clonal dynamics during therapeutic intervention. Sanger sequencing of PCR amplicons may serve as a confirmatory orthogonal method.
Hematological and Pathological Analysis
Automated hematology analyzers are used for CBC measurement on EDTA-anticoagulated blood. Formalin-fixed, paraffin-embedded tissue sections undergo H&E staining for morphology and reticulin silver staining for fibrosis grading according to established semi-quantitative scales. Blinded pathological scoring by a veterinary pathologist is recommended to minimize observer bias.
Flow Cytometry
Multiparameter flow cytometry is employed to quantify lineage composition using markers such as CD45, Gr-1, Mac-1, Ter119, CD41, B220, and CD3, along with GFP to track transduced cells. Intracellular staining for phospho-STAT5 following ex vivo stimulation provides a direct readout of JAK pathway activation.
Applications
The JAK2 V617F mouse model supports a wide spectrum of preclinical and translational research applications:
- Preclinical efficacy evaluation of JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib, including dosing optimization and combination therapy studies
- Investigation of MPN pathogenesis, including mechanisms of myelofibrosis development and clonal evolution
- Study of leukemic transformation from chronic-phase MPN to acute myeloid leukemia
- Identification and validation of pharmacodynamic and predictive biomarkers for JAK-STAT pathway inhibition
- Assessment of therapeutic resistance mechanisms and evaluation of second-line treatment strategies
- Immune microenvironment studies within the spleen and bone marrow niche
- Screening of novel small molecules, antibodies, and targeted degraders directed against JAK2 or downstream effectors
- Comparative efficacy studies supporting IND-enabling toxicology packages
FAQ
How long does it take to establish disease in the JAK2 V617F transplantation model?
Following transplantation of transduced bone marrow, recipient mice typically develop detectable hematological abnormalities within 2 to 3 weeks. Full disease presentation, including significant splenomegaly and erythrocytosis, is generally achieved by 4 weeks, while myelofibrosis progresses over 8 to 16 weeks depending on the experimental configuration.
What is the difference between the transplantation model and the knock-in model?
The transplantation model offers rapid disease onset and is well suited for high-throughput drug screening, whereas the conditional knock-in model drives expression from the endogenous locus, producing a slower, more physiological disease course that better recapitulates human MPN progression, including the evolution from polycythemia to fibrosis.
How is successful model establishment validated?
Validation requires converging evidence from multiple endpoints: confirmation of the mutant allele by molecular assays, characteristic CBC abnormalities such as elevated hematocrit and leukocytosis, macroscopic splenomegaly, histological evidence of extramedullary hematopoiesis and myelofibrosis, and demonstration of constitutive STAT5 phosphorylation in affected hematopoietic cells.
What mouse strain is most appropriate for the transplantation protocol?
BALB/c and C57BL/6 are the most commonly used strains. BALB/c recipients develop a rapidly progressive polycythemia-like phenotype with prominent leukocytosis, while C57BL/6 recipients tend toward a myelofibrosis-oriented phenotype, allowing researchers to select the strain according to the disease aspect under investigation.
Can the model be used to study leukemic transformation?
Yes. When combined with additional genetic lesions such as Tp53 loss or Ezh2 mutation, or through serial transplantation, the JAK2 V617F background supports the study of blast crisis and acute leukemia development, providing a valuable platform for evaluating therapies targeting transformed disease.